PLRX PLIANT THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1746473 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY48.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.3%
ROA-40.5%
ROIC (approx.)-63.7%
Asset turnover—
Leverage & solvency
Liabilities / assets25.5%
Debt / equity0.00x
Current ratio8.05x
Interest coverage-698.18x
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $109.16M | $169.31M |
| SG&A expense | $47.22M | $59.05M |
| Operating income | -$156.37M | -$228.37M |
| Interest expense | $2.56M | $3.02M |
| Pretax income | -$149.30M | -$210.30M |
| Income tax | $0 | $0 |
| Net income | -$149.34M | -$210.30M |
| EBITDA | -$154.68M | -$226.24M |
| EPS (basic) | -2.43 | -3.47 |
| EPS (diluted) | -2.43 | -3.47 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 61.37M | 60.54M |
| Balance sheet | ||
| Cash & equivalents | $45.45M | $72.67M |
| Short-term investments | $145.50M | $284.54M |
| Current assets | $196.45M | $362.26M |
| PP&E, net | $2.94M | $5.53M |
| Total assets | $225.23M | $396.95M |
| Current liabilities | $16.36M | $33.22M |
| Long-term debt | $0 | $30.21M |
| Total debt | $0 | $30.21M |
| Total liabilities | $44.02M | $92.87M |
| Shareholders' equity | $181.21M | $304.08M |
| Net debt | -$45.45M | -$42.46M |
| Shares outstanding | 61.45M | 60.86M |
| Cash flow statement | ||
| Operating cash flow | -$128.34M | -$155.50M |
| Capital expenditure | $374,000 | $3.85M |
| Free cash flow | -$128.71M | -$159.35M |
| Investing cash flow | $134.29M | $140.34M |
| Financing cash flow | -$31.70M | $23.12M |
| Depreciation & amortization | $1.70M | $2.12M |
| Stock-based compensation | $26.23M | $37.63M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.